Esophageal cancer responsive to the combination of immune cell therapy and low-dose nivolumab: two case reports

ConclusionThe combination of adoptive immune cell therapy and an immune checkpoint inhibitor might be a possible treatment strategy for advanced esophageal cancer.Trial registration UMIN000028756. Registered 14 September 2017
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research